Jan 22, 2025, 14:52
Mark Bolton: Comparison of TACE vs EBRT for BCLC A-B HCC
Mark Bolton, Radiation Oncologist, shared a post on X:
“Comparison of TACE vs EBRT for BCLC A-B HCC
Assuming skeptical prior for treatment effect, the probability that EBRT offers better survival than TACE is a whopping 94.2%
Direct inference = directly clinically actionable; can mention at tumor board and to the patient; easily understood. Look at the confusion that arises in Frequentist context: what does “not statistically significantly different mean”? What does one do with that?
Is a reason why TACE is still being done as local control modality in trials simply because of errors of inference? “No difference in survival” is NOT the case; TACE should be kicked to the ash heap because it very very likely results in worse survival than EBRT.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 7, 2025, 16:47
Sep 7, 2025, 16:30
Sep 7, 2025, 16:25